Neurodegenerative diseases (ND) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and fi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BrainChip4MED
Brain on a chip as a preclinical model tool for the screenin...
157K€
Cerrado
NeuroNanoChip
A Nano electrode chip for high resolution high throughput ce...
149K€
Cerrado
NEUROGUIDE
Study of neuronal sensing and migration guidance dynamics in...
96K€
Cerrado
PCIN-2013-065
REDES NEURONALES EN CHIPS DE MICROFLUIDOS PARA EL ESTUDIO DE...
110K€
Cerrado
BRAIN-ACT
Biohybrid Synapses for Interactive Neuronal Networks
2M€
Cerrado
TEC2015-70104-P
PLATAFORMA MICROFLUIDICA 3D DE CULTIVO NEURONAL COMPARTIMENT...
179K€
Cerrado
Información proyecto NOC
Duración del proyecto: 5 meses
Fecha Inicio: 2016-12-07
Fecha Fin: 2017-05-31
Líder del proyecto
MICROBRAIN BIOTECH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Neurodegenerative diseases (ND) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).
MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering turn-key solutions to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (NoC, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models:
- Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness)
- Reduce animal testing
- Predicting human-relevant drug responses
- Compatibility with readouts used in biology & real time visualization
- Reconstitution of complex organ-level physiological functions
NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.